Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Take-home naloxone

Thara Kumar and Hans Rosenberg
CMAJ September 18, 2017 189 (37) E1192; DOI: https://doi.org/10.1503/cmaj.170600
Thara Kumar
Department of Emergency Medicine, University of Ottawa/The Ottawa Hospital, Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Rosenberg
Department of Emergency Medicine, University of Ottawa/The Ottawa Hospital, Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hrosenberg33@gmail.com
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Re: Take-home Naloxone
    Edward Xie
    Posted on: 05 October 2017
  • Posted on: (5 October 2017)
    Page navigation anchor for Re: Take-home Naloxone
    Re: Take-home Naloxone
    • Edward Xie, Emergency physician
    • Other Contributors:
    We thank Kumar and Rosenberg for enhancing care provider knowledge of treatments for opioid abuse and its consequences (1). However, we need to be more precise in how we talk about the opioid crisis: using the term "poisoning" instead of "overdose" would better reflect clinical reality and also change our subconscious thinking patterns to reduce the stigma faced by patients. We ought to be consistent and accurate in our portrayal...
    Show More
    We thank Kumar and Rosenberg for enhancing care provider knowledge of treatments for opioid abuse and its consequences (1). However, we need to be more precise in how we talk about the opioid crisis: using the term "poisoning" instead of "overdose" would better reflect clinical reality and also change our subconscious thinking patterns to reduce the stigma faced by patients. We ought to be consistent and accurate in our portrayal of medical conditions as it affects public attitudes and support for health policies (2). In this context, we've heard many misconceptions about drug use and addictions, such as the idea that supervised injection sites promote substance abuse.

    The term "overdose" connotes personal failure and responsibility, and is a remnant of the old psychosocial model of addiction. This term suggests that the patient a) knows the nature of the substance taken and b) has taken more than what she or he was tolerant to or intended to take (3). "Overdose" also implies that there is a correct dose when none exists for use of illicit formulations. In practice, opioid formulations sold in unregulated markets have variable and unknown potency, so dosing is impossible. In addition, people experience loss of tolerance due to inconsistent use and concurrent illness, so dosing is variable at the individual level. For this reason, we judiciously dose opioids in acute care settings, with careful monitoring.

    Consequently, we suggest that the more precise terms "poisoning" or "intoxication" should be used. These terms accurately label the acute medical illness and are physiologically and medio-legally aligned, corresponding with the international standard disease classification system ICD-10 (4). Reorienting our language with regard to opioids is also compatible with public understanding regarding other substances: we say "alcohol poisoning" or "intoxication", and not "alcohol overdose".

    With these more accurate terms, providers may be cued to consider and address the two separate health needs present: Acute poisoning or intoxication, and The contributory conditions: uncontrolled pain, mental illness, drug dependence or addiction etc.

    As we update our understanding of substance use disorders from a psychosocial to a comprehensive medical model, it is imperative that we also update the language we use to accurately reflect the medical process in place. For the public, this can avoid moral judgements and confusion. Our hope is that using the right words can lead to more effective management of the opioid crisis as a public health emergency.

    Edward Xie MD, CCFP(EM), DTM&H Emergency Physician, University Health Network Clinical Lecturer, University of Toronto

    Samantha Green MD, CCFP DFCM, University of Toronto

    Nitasha Puri MD CCFP dipABAM

    Hasan Sheikh, BSc., M.D. CCFP(EM) ED physician, University Health Network

    References

    1. Kumar T and Rosenberg H. Five Things to Know About Take-home naloxone. CMAJ. 2017; 189:E1192.

    2. Kelly J.F., Saitz R., Wakeman S. Language, Substance Use Disorders, and Policy: The Need to Reach Consensus on an "Addictionary". Alcoholism Treatment Quarterly. 2016; 34(1): 116-123.

    3. Behar E, Rowe C, Santos GM, Murphy S, Coffin PO. Primary Care Patient Experience with Naloxone Prescription. Ann Fam Med. 2016 Sep;14(5):431-6

    4. Canadian Institute for Health Information. International Statistical Classification of Diseases and Related Health Problems, 10th revision, Canada. Canadian Institute for Health Information. Ottawa, Canada. 2009.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (37)
CMAJ
Vol. 189, Issue 37
18 Sep 2017
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Take-home naloxone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Take-home naloxone
Thara Kumar, Hans Rosenberg
CMAJ Sep 2017, 189 (37) E1192; DOI: 10.1503/cmaj.170600

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Take-home naloxone
Thara Kumar, Hans Rosenberg
CMAJ Sep 2017, 189 (37) E1192; DOI: 10.1503/cmaj.170600
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Naloxone is available without prescription in Canada
    • Most take-home naloxone kits contain similar equipment
    • Multiple doses of naloxone may be required for overdoses related to high-potency opioids
    • Take-home naloxone kits may reduce overdose-related mortality
    • Take-home naloxone kits are not only for patients with current opioid abuse
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Updating our language around substance use disorders
  • PubMed
  • Google Scholar

Cited By...

  • Updating our language around substance use disorders
  • Google Scholar

More in this TOC Section

  • Phthiriasis palpebrarum
  • Penicillin allergy delabelling in pregnancy
  • Penicillin allergy delabelling of patients at risk of sexually transmitted infections in primary care
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire